Latest ViiV Healthcare Stories
Initial Investment to Help Research, Identify and Apply Innovative Solutions in Baltimore, Maryland and Jackson, Mississippi - Two of the Cities Hardest Hit by HIV/AIDS RESEARCH TRIANGLE
LONDON and PITTSBURGH, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
PITTSBURGH and LONDON, Dec. 4, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that its subsidiary Mylan Laboratories Limited has received tentative approval from the U.S.
Positive Action Southern Initiative Commitment Continues with New Grants Awarded to Seven Organizations, Bringing Total Funding for Grassroots Projects to More than 2.8 Million to Date RESEARCH
Agreement is ViiV Healthcare's first external collaboration for development of a two drug single-tablet combining dolutegravir and rilpivirine LONDON, June 12, 2014 /PRNewswire/ -- ViiV Healthcare
Key findings point to significant differences between treated and untreated people living with HIV RESEARCH TRIANGLE PARK, N.C., June 10, 2014 /PRNewswire/ -- ViiV Healthcare today announced
Elizabeth Glaser Pediatric AIDS Foundation Applauds Agreement between the Medicines Patent Pool and ViiV Healthcare WASHINGTON, April 1, 2014 /PRNewswire-USNewswire/ --
GENEVA, April 1, 2014 /PRNewswire/ -- Access to dolutegravir could improve millions of lives in developing
- Timely collaborations underscore ViiV Healthcare's commitment to increase access to life-saving HIV medicines for children and adults in the developing world LONDON, April 1, 2014 /PRNewswire/
- An armed gangster.